Allele *2 of the HS1,2A enhancer of the Ig regulatory region associates with rheumatoid arthritis

B Tolusso,1 D Frezza,2 C Mattioli,2 A L Fedele,1 S Bosello,1 F Faustini,1 G Peluso,1 V Giambra,2 D Pietrapertosa,1 A Morelli,1 E Gremese,1 M De Santis,1 G F Ferraccioli2

ABSTRACT

Objective: To investigate the role of the HS1,2 enhancer polymorphisms as a new candidate marker for rheumatoid arthritis (RA) and to define the possible association with autoantibody positivity and clinical outcome.

Methods: Genomic DNA was obtained from two cohorts of patients with RA (100 with early RA (ERA) and 114 with longstanding RA (LSRA)) and from 248 gender-matched controls from the same geographical area. Clinical and immunological characteristics were recorded for all the patients.

Results: The percentage of the 2/2 genotype was higher in patients with ERA (27.0%) and in patients with LSRA (34.2%), than in controls (14.9%) (ERA: OR = 2.11 (95% CI 1.20 to 3.70) vs controls; LSRA: OR = 2.96 (95% CI 1.76 to 5.00) vs controls). A lower representation of allele *3 was present in patients with ERA (2.0%) than in controls (6.0%; OR = 0.32 (95% CI 0.11 to 0.91)). No significant associations were found between polymorphisms and autoantibodies positivity.

Conclusion: The HS1,2A allele *2 associates with early and longstanding RA.

Studies of twins clearly show a genetic contribution to disease susceptibility in rheumatoid arthritis (RA).1 The most important genetic risk factor is in the polymorphic HLA region. The HLA-DRB1 alleles, encoding for shared epitope, confer a higher risk for development of RA.2 The association exists for RA that is characterised by the presence of anti-cyclic citrullinated peptide (anti-CCP) antibodies.3 Other genetic associations have been found in recent years (eg, PTPN22).4

Recently, a polymorphism of the enhancer HS1,2A of the Ig heavy 3′ regulatory region (IgH 3′RR-1) at the 3′ of the constant alpha (C-alpha) genes has been associated with IgA nephritis, coeliac disease, systemic sclerosis and psoriasis.5–8 In these diseases, the variation of allelic frequencies involves allele *2, which has one consensus site for the NF-kB transcription factor missing in the second more frequent allele *1.9 The IgH 3′ regulatory region is active in the transcription of the heavy constant genes for class switch recombination and in the Ig transcription.9

The major aim of this study was to investigate a possible association of HS1,2A polymorphism with RA, the presence of autoantibodies and finally, to look for a possible relationship with response to treatment.

PATIENTS AND METHODS

Patients

A cohort of 100 patients with early RA (ERA, disease duration <12 months), at the Division of Rheumatology of the Catholic University (Rome, Italy) was studied. Patients fulfilled the American College of Rheumatology criteria for RA.11 The disease status for each patient was assessed. Detailed assessment at study entry (baseline), at 6 months and at 1 year included the disease activity score (DAS), complete tender and swollen joint count, acute-phase reactants (erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)), as well as visual analogue scale (0–100 mm) for global disease activity. All patients’ serum samples were tested for anti-CCP, IgM rheumatoid factor (RF) and IgG RF autoantibodies, following ELISA standard techniques. Treatment was based on methotrexate (MTX) for 3 months (up to 20–25 mg/week) and etanercept after 3 months if the DAS was not sufficiently lowered with MTX only, to reach clinical remission (DAS44 <1.6).

A second, completely independent cohort of 114 patients with RA with a long disease duration (more than 1-year’s disease duration, longstanding RA (LSRA)) was included in the study and the same measures for disease activity were collected. All these patients with LSRA were receiving MTX in combination with the tumour necrosis factor α blocker because of severe, progressive disease.

Collection of DNA samples

Genomic DNA was isolated from peripheral venous blood of patients and controls with a FlexiGene DNA kit (Qiagen, Valencia, California, USA), according to the instruction given by manufacturer. The control sample comprised 248 unrelated, healthy controls of both sexes. Each control was asked to supply name, birthplace, language and ethnicity for three generations in order to exclude recent admixture. The patients and control subjects were white subjects of Italian origin, from the same geographical area and gave their informed consent to participate in the study.

HS1,2A genotyping

Alleles of the HS1,2A enhancer were determined through two PCRs. The first was on genomic DNA, selective for the IgH 3′RR at the 3′ of C-alpha 1 gene and amplified a fragment of 5404 bp, the second was a nested PCR to amplify the polymorphic HS1,2A fragment varying from 465 to 287 bp (fig 1). The first PCR was performed with primers SA2.5 forward 5′-GGATCCCTGTTCCGTGACATCAG-3′ and A2R reverse 5′-CCCCCTTGTGCCAACCCTG-3′; PCRs were carried out in 50 μl reaction volume containing...
A) Map of the Ig heavy chain cluster showing the duplication of four constant regions along with the two 3’ regulatory regions (copy A and copy B). The three enhancers of both 3’RRs are conserved also in mice, separated by intervening sequences highly conserved for the quality of repeats units but not for number. (B) Only the enhancer HS1,2 was found to be polymorphic. The alleles of the A and B regions are identical. On the right side of the alleles is indicated the length of the polymorphic region of each allele. The polymorphism is based on the duplicated element of 38 bp minisatellite (blue strips) from one to four times separated by spacers (Sp) of 20 bp (green), 16 bp (violet) and 14 bp (red). The polymorphic region of allele *4 has the substitution of the 17 bp element 5’ (El) (red spots) with a 31 bp El (orange diamonds) harbouring the consensus sequence “c”. The letters listed at the bottom of the figure correspond respectively to “in silico” predicted transcription factors. The site “a” within the core not polymorphic of the enhancer HS1,2 has the consensus for CEBP, CMYB; “b” presents the consensus for SP1; “c” has the site for AP4, E47, MYOD and \( \mu E5 \); “d” presents the consensus for IK2, MZF1 and NF-\( \kappa B \) (unpublished data).

Figure 1

Categorical and quantitative variables were respectively described as numbers (%) and mean (SD). Sample size calculations were based on the following assumptions: power 80%, confidence 95%, estimated difference to test between 2/2 genotype frequency of cases and controls 15%, ratio between cases and controls 1:2. A minimum of 97 cases and 194 controls was derived from these calculations. A Mann-Whitney test was used to compare continuous variables. Categorical variables were analysed using \( \chi^2 \) test or Fisher test, depending on sample size restrictions, and the odd ratios (ORs) with 95% CI were calculated. A value of \( p<0.05 \) was considered significant. The Hardy–Weinberg equilibrium was calculated for all the genotyped groups.

RESULTS

Study participants’ characteristics

The study cohorts consisted of 100 patients with ERA, enrolled before any treatment with disease-modifying antirheumatic drugs had been initiated and 114 with LSRA. Table 1 shows the main demographic, clinical and serological features of the patients with RA.

Distribution of HS1.2A genotypes in patients with RA and in controls

The genotype distribution of the HS1.2A polymorphism was significantly different between patients with ERA and controls \( (\chi^2 = 15.20, \ p = 0.004) \) and the percentage of the 2/2 genotype was higher in patients with ERA (27.0%) than in the control group (14.9%; \( \text{OR} = 1.73 \text{ (95\% CI 1.11 to 2.68)} \); \( p = 0.008 \) (table 2). The frequency of the allele *2 was increased in patients with ERA (55.0%) as compared with the control group (40.0%; \( \text{OR} = 1.73 \text{ (95\% CI 1.24 to 2.40)} \); \( p = 0.001 \)), whereas a lower representation of the allele *1 (2%) in patients with ERA was seen when compared with the controls (6%; \( \text{OR} = 0.32 \text{ (95\% CI 0.11 to 0.91)} \); \( p = 0.05 \)). The alleles *1 and 4 had comparable frequency in patients with ERA (allele *1: 36.5% and allele *4: 35.5%) as compared with the control group (6%; \( \text{OR} = 0.52 \text{ (95\% CI 0.11 to 0.91)} \); \( p = 0.05 \)).

In LSRA, 34.2% of the patients carried the 2/2 genotype \( (p<0.001 \text{ vs controls}; \text{table 2}) \) and the frequency of the allele *2 was 62.7% \( \text{(OR} = 2.58 \text{ (95\% CI 1.86 to 3.56); p<0.001)} \). A lower representation of allele *5 and allele *4 was present in LSRA versus controls (allele *5: 13%; \( \text{OR} = 0.21 \text{ (95\% CI 0.06 to 0.69); p = 0.05} \)); allele *4: 1.3%, \( \text{OR} = 0.12 \text{ (95\% CI 0.04 to 0.37);}"
Table 1 Demographic, clinical and laboratory characteristics of patients with early rheumatoid arthritis at baseline, and of patients with longstanding rheumatoid arthritis at the moment of the analysis

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Patients with ERA (n = 100)</th>
<th>LSRA (n = 114)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n (%)</td>
<td>75 (75.0)</td>
<td>97 (85.1)</td>
</tr>
<tr>
<td>Age (years), mean (SD)</td>
<td>54.9 (13.8)</td>
<td>57.1 (13.6)</td>
</tr>
<tr>
<td>Disease duration (years), mean (SD)</td>
<td>6.8 (0.3)</td>
<td>15.7 (10.0)</td>
</tr>
<tr>
<td>Tender joint count, mean (SD)</td>
<td>15.5 (10.1)</td>
<td>8.3 (8.9)</td>
</tr>
<tr>
<td>Swollen joint count, mean (SD)</td>
<td>11.4 (8.7)</td>
<td>5.3 (6.2)</td>
</tr>
<tr>
<td>Anti-CCP (U/ml)</td>
<td>48.6 (63.4)</td>
<td>49.6 (91.3)</td>
</tr>
<tr>
<td>Anti-CCP (U/ml)</td>
<td>65.0 (65.0)</td>
<td>78 (68.4)</td>
</tr>
<tr>
<td>IgM RF (U/ml)</td>
<td>61.9 (98.6)</td>
<td>45.7 (78.8)</td>
</tr>
<tr>
<td>IgM RF (U/ml)</td>
<td>54.0 (54.0)</td>
<td>47 (41.2)</td>
</tr>
<tr>
<td>IgA RF (U/ml)</td>
<td>75.6 (149.9)</td>
<td>52.0 (122.2)</td>
</tr>
<tr>
<td>IgA RF (U/ml)</td>
<td>43.0 (43.0)</td>
<td>33 (28.9)</td>
</tr>
<tr>
<td>CRP (mg/l), mean (SD)</td>
<td>24.1 (30.6)</td>
<td>24.9 (11.9)</td>
</tr>
<tr>
<td>ESR (mm/1st h), mean (SD)</td>
<td>40.6 (24.6)</td>
<td>23.7 (19.5)</td>
</tr>
<tr>
<td>HAQ, mean (SD)</td>
<td>3.9 (1.4)</td>
<td>2.7 (1.4)</td>
</tr>
<tr>
<td><strong>p &lt; 0.001</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Controls (n = 248)</th>
<th>Patients with ERA (n = 100)</th>
<th>Patients with LSRA (n = 114)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HAQ, mean (SD)</td>
<td>1.24 (0.78)</td>
<td>1.05 (0.80)</td>
<td></td>
</tr>
</tbody>
</table>

\[\text{anti-CCP, anti-cyclic citrullinated protein; CRP, C-reactive protein; DAS, disease activity score; ERA, early rheumatoid arthritis; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; LSRA, longstanding rheumatoid arthritis; RF, rheumatoid factor.}\]

**DISCUSSION**

RA is characterised by polyclonal B-cell activation and production of autoantibodies even before the appearance of arthritis, suggesting lack of tolerance as primary event conditionning autoreactivity. These data suggest an important role for B lymphocytes in the pathogenesis of RA as contributors of autoimmunity, as antigen-presenting cells and T-cell stimulators, and of inflammation as cytokine producers.

The central human enhancer HS1,2A of IgH 3’RR located in chromosome 14,q32 was polymorphic in humans and the involvement of allele *2 in the genetic predisposition of immune-related diseases has already been noted. We found that allele *2 of the HS1,2A enhancer is significantly more common in patients with ERA than in healthy controls, and more common in patients with RA with an aggressive disease not responding to treatment with common disease-modifying antirheumatic drugs (LSRA). Allele *2 is not associated directly with the presence of autoantibodies. The trend suggesting that HS1,2A allele *2 might also play a role in limiting the occurrence of disease remission in patients with RA under adopted treatment needs confirmation in a larger cohort with a longer follow-up.

There are no data reported with wide genome scans on the association of chromosome 14 (region q32) with RA disease; this may be because all studies focused mainly on the analysis of translated and transcribed genes and not on cis-acting regulatory regions. It might be interesting to develop a study for multiple association analysis of the risk factors so far studied in different patient populations with different techniques, including wide genome screening if any, in order to obtain conclusive information.

Table 2 Distribution of genotypes of the HS1,2A polymorphism in patients with early rheumatoid arthritis (ERA), patients with longstanding rheumatoid arthritis (LSRA) and controls

<table>
<thead>
<tr>
<th>HS1,2A polymorphism genotype</th>
<th>Controls (n = 248)</th>
<th>Patients with ERA (n = 100)</th>
<th>OR (95% CI)</th>
<th>p Value</th>
<th>Patients with LSRA (n = 114)</th>
<th>OR (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/1</td>
<td>52 (21.0)</td>
<td>11 (11.0)</td>
<td>10 (8.8)</td>
<td>0.03</td>
<td>39 (34.2)</td>
<td>2.96 (1.76 to 5.00)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>2/2</td>
<td>37 (14.9)</td>
<td>27 (27.0)</td>
<td>21.2 (12.0 to 3.70)</td>
<td>0.008</td>
<td>39 (34.2)</td>
<td>2.96 (1.76 to 5.00)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>3/3</td>
<td>2 (0.8)</td>
<td>10 (10.0)</td>
<td>0.02 (10.32)</td>
<td>1.00</td>
<td>39 (34.2)</td>
<td>2.96 (1.76 to 5.00)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>4/4</td>
<td>4 (1.6)</td>
<td>2 (2.0)</td>
<td>0.02 (8.24 to 12.22)</td>
<td>0.13</td>
<td>39 (34.2)</td>
<td>2.96 (1.76 to 5.00)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>1/2</td>
<td>64 (33.9)</td>
<td>46 (46.0)</td>
<td>1.04 (1.20 to 3.70)</td>
<td>0.007</td>
<td>39 (34.2)</td>
<td>2.96 (1.76 to 5.00)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>1/3</td>
<td>12 (4.9)</td>
<td>9 (9.0)</td>
<td>0.01 (1.20 to 2.20)</td>
<td>0.57</td>
<td>39 (34.2)</td>
<td>2.96 (1.76 to 5.00)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>1/4</td>
<td>18 (7.3)</td>
<td>2 (2.0)</td>
<td>0.06 (0.08 to 1.15)</td>
<td>0.07</td>
<td>39 (34.2)</td>
<td>2.96 (1.76 to 5.00)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>2/3</td>
<td>13 (5.2)</td>
<td>1 (1.0)</td>
<td>0.02 (1.20 to 1.42)</td>
<td>0.08</td>
<td>3 (2.6)</td>
<td>0.90 (0.14 to 1.75)</td>
<td>0.40</td>
</tr>
<tr>
<td>2/4</td>
<td>25 (10.1)</td>
<td>5 (5.0)</td>
<td>0.17 (1.20 to 1.26)</td>
<td>0.14</td>
<td>3 (2.6)</td>
<td>0.24 (0.07 to 0.82)</td>
<td>0.014</td>
</tr>
<tr>
<td>3/4</td>
<td>1 (0.4)</td>
<td>–</td>
<td>0.03 (0.03 to 20.34)</td>
<td>1.00</td>
<td>–</td>
<td>0.72 (0.03 to 17.84)</td>
<td>1.00</td>
</tr>
</tbody>
</table>

*p Values are calculated from χ² tests performed in patients (ERA and LSRA) versus controls.
In “silico” predictive analysis shows in the allele *2 of the HS1,2A enhancer polymorphism the presence of a consensus binding site for NF-kB, absent in allele *1. Preliminary data suggest that allele *2 of the HS1,2A polymorphism establishes a higher affinity with NF-kB and its link with the transcription (unpublished data). If this were the case the association with RA could be more fully interpreted.

**Funding:** This research was supported by the funding of the Catholic University of Sacred Heart of Rome and University of Tor Vergata, Rome (MIUR PRIN N.20073RH73W_003).

**Competing interests:** None.

**Ethics approval:** Ethics committee approval obtained.

**REFERENCES**


Allele *2 of the HS1,2A enhancer of the Ig regulatory region associates with rheumatoid arthritis

B Tolusso, D Frezza, C Mattioli, A L Fedele, S Bosello, F Faustini, G Peluso, V Giambra, D Pietrapertosa, A Morelli, E Gremese, M De Santis and G F Ferraccioli

*Ann Rheum Dis* 2009 68: 416-419 originally published online October 24, 2008
doi: 10.1136/ard.2008.095414

Updated information and services can be found at:
[http://ard.bmj.com/content/68/3/416](http://ard.bmj.com/content/68/3/416)

**References**

This article cites 15 articles, 1 of which you can access for free at:
[http://ard.bmj.com/content/68/3/416#BIBL](http://ard.bmj.com/content/68/3/416#BIBL)

**Open Access**

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Open access (604)
- Genetics (968)
- Connective tissue disease (4253)
- Degenerative joint disease (4641)
- Immunology (including allergy) (5144)
- Musculoskeletal syndromes (4951)
- Rheumatoid arthritis (3258)

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)